HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C).

Abstract
Recent preclinical studies suggest that vaccination following adoptive transfer of CD8(+) T cells into a lymphopenic host can augment the therapeutic antitumor responses of the transferred cells. However, the mechanism by which the lymphopenic microenvironment benefits Ag-specific CD8(+) T cell responses remains elusive. We show herein that induction of lymphodepletion by a single 4 mg cyclophosphamide (CTX) treatment induces a marked expansion of immature dendritic cells (DCs) in the peripheral blood on days 8-16 post-CTX (termed restoration phase). In vitro, these DCs were functional, because they showed normal phagocytosis and effective Ag presentation capability upon activation. In vivo, administration of the TLR3 agonist poly(I:C) at the peak of DC expansion (day 12 postlymphopenia) induced inflammatory cytokine production and increases in the number of activated DCs in lymph nodes. Importantly, boosting with gp100(25-33) melanoma peptide combined with poly(I:C) 12 days after an initial priming with the same regimen significantly increased the expansion and the antitumor efficacy of adoptively transferred pmel-1 CD8(+) T cells. These responses were abrogated after depletion of activated DCs during Ag boosting. In conclusion, our data show that CTX treatment induces, during the restoration phase, expansion of immature DCs, which are functional and can be exploited in vivo to foster more effective antitumor adoptive immunotherapy strategies.
AuthorsMohamed L Salem, C Marcela Díaz-Montero, Amir A Al-Khami, Sabry A El-Naggar, Osama Naga, Alberto J Montero, Ahmed Khafagy, David J Cole
JournalJournal of immunology (Baltimore, Md. : 1950) (J Immunol) Vol. 182 Issue 4 Pg. 2030-40 (Feb 15 2009) ISSN: 1550-6606 [Electronic] United States
PMID19201856 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Cancer Vaccines
  • Immunosuppressive Agents
  • Interferon Inducers
  • Membrane Glycoproteins
  • Pmel protein, mouse
  • TLR3 protein, mouse
  • Toll-Like Receptor 3
  • gp100 Melanoma Antigen
  • Cyclophosphamide
  • Poly I-C
Topics
  • Animals
  • CD8-Positive T-Lymphocytes (immunology, transplantation)
  • Cancer Vaccines (immunology)
  • Cyclophosphamide (toxicity)
  • Dendritic Cells (drug effects, immunology)
  • Flow Cytometry
  • Immunosuppressive Agents (toxicity)
  • Immunotherapy, Adoptive (methods)
  • Interferon Inducers (immunology)
  • Lymphopenia (chemically induced)
  • Melanoma, Experimental (immunology, therapy)
  • Membrane Glycoproteins (immunology)
  • Mice
  • Poly I-C (immunology)
  • Toll-Like Receptor 3 (immunology)
  • Transplantation Conditioning (methods)
  • gp100 Melanoma Antigen

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: